NASDAQ · Biotechnology

RLAY (RLAY) Stock

$18.37 +0.44% NASDAQ: RLAY Healthcare

Valuation

MetricValue
Price$18.37
Market Cap$3.22B
P/E Ratio-7.52
P/B Ratio4.09
P/S Ratio241.83
EPS (TTM)$-1.61
52-Week High$20.75
52-Week Low$3.02
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-48.68%
ROA-44.44%
ROCE-53.44%
Gross Margin-2020.00%
Operating Margin-2020.00%
Net Margin-25.54%
Debt/Equity0.05
Current Ratio22.23

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$1.0M$26.0M$10.0M$15.0M
Operating Profit$-365.0M$-299.0M$-373.0M$-372.0M$-303.0M
Net Profit$-364.0M$-291.0M$-342.0M$-338.0M$-276.0M
EPS$-3.82$-2.59$-2.79$-2.36$-1.61
Op Margin-12040.2%-21670.9%-1460.1%-3722.1%-1971.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0B$1.1B$844.0M$871.0M$621.0M
Total Liabilities$111.0M$150.0M$92.0M$94.0M$54.0M
Cash$280.0M$999.0M$144.0M$124.0M$84.0M
Borrowings$23.0M$58.0M$53.0M$49.0M$32.0M

Latest News

Canaccord Genuity Initiates Relay Therapeutics at Buy With $29 Price Target MT Newswires · Jul 16, 2026 Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Relay Therapeutics Insider Sold Shares Worth $943,736, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year Motley Fool · Jun 30, 2026 Relay Therapeutics Insider Sold Shares Worth $1,583,145, According to a Recent SEC Filing MT Newswires · Jun 24, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-74.0M$-229.0M$-300.0M$-249.0M$-235.0M
Investing Cash Flow$-483.0M$-198.0M$254.0M$-43.0M$192.0M
Financing Cash Flow$6.0M$5.0M$4.0M$4.0M$0
Net Cash Flow$-166.0M$-128.0M$-8.0M$-20.0M$-41.0M
Free Cash Flow$-78.0M$-239.0M$-304.0M$-251.0M$-236.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-8.26%
Quick Ratio22.13
Interest Coverage—
Return 1Y423.99%
Return 3Y56.90%
Return 5Y-43.22%

Ownership

Insiders Held1.37%
Institutions Held88.06%
Institutions Float Held89.28%
Institutional HolderSharesReport Date
SB Investment Advisers (UK) LTD27,904,9632026-03-31
Commodore Capital Lp17,000,0002026-03-31
Casdin Capital, LLC14,418,5742026-03-31
Blackrock Inc.12,975,2992026-03-31
Perceptive Advisors Llc9,751,1412026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMLX $22.82 -5.66% -8.69 $2.54B 0.00%
CVACCureVac N.V. $4.66 +0.00% 5.69 $1.05B 0.00%
IMTX $8.24 -4.52% -4.98 $1.10B 0.00%
INBXInhibrx Biosciences Inc. $81.54 -0.01% -9.72 $1.20B 0.00%
NKTR $70.68 -0.13% -6.95 $1.38B 0.00%

About RLAY

RLAY stock trades at $18.37 with a market capitalization of $3.22B. The stock is valued at a price-to-earnings (P/E) ratio of -7.52, price-to-book of 4.09, price-to-sales of 241.83. Over the past 52 weeks the stock has ranged between $3.02 and $20.75, and currently trades 11.5% below its 52-week high.

On profitability, RLAY generates a return on equity (ROE) of -48.68%, return on capital employed of -53.44%, an operating margin of -2020.00%, a net profit margin of -25.54%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides